Form 4 for LONA LeonaBio, Inc.

Accepted 2022-01-20 00:00:00 ET · period of report 2022-01-18 · accession 0001209191-22-004120 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-01-20	2021-11-18	LONA	MOEBIUS HANS	Chief Medical Off	A - Grant	$12.51	+829	31.3K	+3%	+$10.4K
D	2022-01-20	2022-01-18	LONA	MOEBIUS HANS	Chief Medical Off	A - Grant	$0.00	+180.0K	180.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-11-18	A	A	829	$12.51	31,256	D	—	—	(F1) The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c). (F2) The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021. (F3) In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021.
2	Derivative	Stock Option (Right to Buy)	2022-01-18	A	A	180,000	$0.00	180,000	D	$10.64 · — to 2032-01-17	180,000 Common Stock	(F4) One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter.